{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:25:48Z","timestamp":1783607148239,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.urolonc.2024.10.012","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:42:53Z","timestamp":1732520573000},"page":"390.e13-390.e22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Mohamad","family":"Abou Chakra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"McElree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.10.012_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.012_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.012_bib0004","first-page":"255","article-title":"Management of high-risk non-muscle invasive bladder cancer","volume":"64","author":"Brausi","year":"2012","journal-title":"Minerva Urol Nefrol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/21681805.2020.1851763","article-title":"Radical cystectomy compared to intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer - is there a long-term survival difference? A Swedish nationwide analysis","volume":"55","author":"Wang","year":"2021","journal-title":"Scand J Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2024.10.012_bib0006","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.3390\/cancers14153797","article-title":"Effectiveness of early radical cystectomy for high-risk non-muscle invasive bladder cancer","volume":"14","author":"Diamant","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.012_bib0007","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.10939.x","article-title":"Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome","volume":"110","author":"Turker","year":"2012","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.012_bib0008","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European association of urology very high-risk non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urolonc.2021.09.022","article-title":"Critical shortage in BCG immunotherapy: How did we get here and where will it take us?","volume":"40","author":"Harvey","year":"2022","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.012_bib0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14656566.2024.2310073","article-title":"Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?","volume":"25","author":"Abou Chakra","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2024.10.012_bib0013","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1442-2042.2012.03089.x","article-title":"Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer","volume":"19","author":"Lightfoot","year":"2012","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.10.012_bib0014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A Phase ii trial of intravesical gemcitabine and docetaxel in the treatment of bacillus calmette-gu\u00e9rin\u2012na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.10.012_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical bcg and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2024.10.012_bib0017","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.10.012_bib0018","doi-asserted-by":"crossref","first-page":"275.e1","DOI":"10.1016\/j.urolonc.2022.02.004","article-title":"Histological variants of non-muscle invasive bladder cancer: survival outcomes of radical cystectomy vs. bladder preservation therapy","volume":"40","author":"Dursun","year":"2022","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.012_bib0019","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.euf.2021.07.015","article-title":"Survival outcomes after immediate radical cystectomy versus conservative management with bacillus Calmette-Gu\u00e9rin among T1 high-grade micropapillary bladder cancer patients: results from a multicentre collaboration","volume":"8","author":"Lonati","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"9","key":"10.1016\/j.urolonc.2024.10.012_bib0020","doi-asserted-by":"crossref","first-page":"289.e13","DOI":"10.1016\/j.urolonc.2024.05.006","article-title":"Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer","volume":"42","author":"Abou Chakra","year":"2024","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.10.012_bib0021","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10147-022-02127-7","article-title":"Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Gu\u00e9rin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data","volume":"27","author":"Tomida","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.10.012_bib0022","doi-asserted-by":"crossref","first-page":"490.e13","DOI":"10.1016\/j.urolonc.2022.05.016","article-title":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","volume":"40","author":"Ferro","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.10.012_bib0023","doi-asserted-by":"crossref","unstructured":"Alexander CM, McElree IM, Mott SL, et al. \u201cOncologic Outcomes Of Bladder-Sparing Management For High-Grade Non-Invasive Urothelial Carcinoma Of The Prostatic Urethra.\u201d Urologic Oncology 42: S45\u201346.","DOI":"10.1016\/j.urolonc.2024.01.144"},{"key":"10.1016\/j.urolonc.2024.10.012_bib0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12894-016-0122-1","article-title":"Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Gu\u00e9rin","volume":"16","author":"Fukumoto","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2024.10.012_bib0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","article-title":"Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes","volume":"53","author":"Tan","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"7","key":"10.1016\/j.urolonc.2024.10.012_bib0026","first-page":"755","article-title":"Population-based assessment of racial\/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer","volume":"28","author":"Williams","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0027","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.10.012_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.urolonc.2024.10.012_bib0029","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2023.04.005","article-title":"Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis","volume":"41","author":"Bukavina","year":"2023","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:57Z","timestamp":1762363977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1078143924006926"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}